What is FeelBetter?
Founded in 2018 and headquartered in Tel Aviv, Israel, FeelBetter operates as a specialized medication management technology company. The firm focuses on developing sophisticated software platforms designed to assist healthcare providers and organizations in managing complex patient medication profiles. By utilizing AI-driven insights, FeelBetter addresses the critical challenges of polypharmacy and adverse drug events, positioning itself as an essential partner for health systems aiming to improve clinical outcomes and reduce operational costs.
The company's market position is defined by its commitment to evidence-based technology that simplifies the medication reconciliation process. Through its unique algorithmic approach, FeelBetter enables clinicians to make informed decisions, thereby enhancing the quality of care for patients with chronic conditions. This focus on high-impact, scalable technology has made the company a focal point for venture capital firms specializing in the intersection of healthcare and data science.
How much funding has FeelBetter raised?
FeelBetter has raised a total of $11.8M across 2 funding rounds:
Other Financing Round
$5.9M
Other Financing Round
$5.9M
Other Financing Round (2023): $5.9M with participation from Random Forest VC, Triventures, Firstime Ventures, and The Group Ventures
Other Financing Round (2023): $5.9M led by Random Forest VC, The Group Ventures, Triventures, and Firstime Ventures
Key Investors in FeelBetter
Random Forest VC
A boutique early-stage fund based in Israel that specializes in investing in AI and ML ventures, focusing on market-disruptive technologies.
Triventures
A global venture capital fund that invests in early-stage companies with innovative breakthroughs in healthcare, bio-convergence, and data-driven technologies.
Firstime Ventures
An investment firm focused on supporting companies that align with the United Nations Sustainable Development Goals, with a specific emphasis on digital health solutions.
What's next for FeelBetter?
With the successful closure of this major strategic investment, FeelBetter is poised to enter a new phase of enterprise-level expansion. The company is expected to prioritize the scaling of its commercial operations, particularly in international markets where the demand for digital health solutions is surging. Strategic initiatives will likely include the enhancement of its core product suite, further integration with electronic health record systems, and the expansion of its clinical research partnerships.
The influx of capital provides the necessary runway to deepen its technological moat, ensuring that FeelBetter remains a leader in the medication management space. As the firm transitions from its foundational growth stage to a more mature enterprise model, the focus will shift toward long-term operational resilience and the continued pursuit of sustainable, data-driven healthcare innovation.
